Multivariable models adjusted for mutation status of BCOR, ASXL1, and RUNX1, which were more prevalent in STAG2-mutated AML patients, demonstrated no independent impact of mutated STAG2 on patient outcome while these co-mutations had varying individual prognostic impact. This evidence concerns the gene ASXL1 and acute myeloid leukemia.